BR112018001511A2 - ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano - Google Patents

?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano

Info

Publication number
BR112018001511A2
BR112018001511A2 BR112018001511A BR112018001511A BR112018001511A2 BR 112018001511 A2 BR112018001511 A2 BR 112018001511A2 BR 112018001511 A BR112018001511 A BR 112018001511A BR 112018001511 A BR112018001511 A BR 112018001511A BR 112018001511 A2 BR112018001511 A2 BR 112018001511A2
Authority
BR
Brazil
Prior art keywords
aqueous solution
low conductivity
producing
methods
human igg1
Prior art date
Application number
BR112018001511A
Other languages
English (en)
Inventor
Kleinjans Annika
Tran Benjamin
Spensberger Bernhard
KOPP Carina
Zettl Frank
Schwendner Klaus
Wong Marc
Wiedmann Michael
Mcdonald Paul
St John Richard
Falkenstein Roberto
Erickson Ryan
Koehnlein Wolfgang
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018001511(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of BR112018001511A2 publication Critical patent/BR112018001511A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

a presente invenção refere-se a um método de purificação de anticorpos por meio de redução do teor de proteína de célula hospedeira. o método emprega uma etapa de lavagem com solução aquosa com baixa condutividade em cromatografia de afinidade.
BR112018001511A 2015-08-21 2016-08-18 ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano BR112018001511A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208523P 2015-08-21 2015-08-21
PCT/EP2016/069604 WO2017032686A1 (en) 2015-08-21 2016-08-18 Method for the reduction of host cell proteins in affinity chromatography

Publications (1)

Publication Number Publication Date
BR112018001511A2 true BR112018001511A2 (pt) 2018-09-18

Family

ID=56802471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001511A BR112018001511A2 (pt) 2015-08-21 2016-08-18 ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano

Country Status (16)

Country Link
US (2) US20180186832A1 (pt)
EP (1) EP3337812B1 (pt)
JP (3) JP6968055B2 (pt)
KR (1) KR20180034500A (pt)
CN (2) CN107849087B (pt)
AU (1) AU2016312909B2 (pt)
BR (1) BR112018001511A2 (pt)
CA (1) CA2992420A1 (pt)
ES (1) ES2877532T3 (pt)
HK (1) HK1251584A1 (pt)
HR (1) HRP20211026T1 (pt)
IL (1) IL257146A (pt)
MX (1) MX2018001536A (pt)
PL (1) PL3337812T3 (pt)
SI (1) SI3337812T1 (pt)
WO (1) WO2017032686A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040618A2 (en) 2014-09-10 2016-03-17 The Procter & Gamble Company Nonwoven web
JP7073253B2 (ja) 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
BR112018001511A2 (pt) 2015-08-21 2018-09-18 Hoffmann La Roche ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano
KR20200141473A (ko) * 2018-05-04 2020-12-18 시그마-알드리치 컴퍼니., 엘엘씨 숙주 세포 단백질의 감소된 수준을 갖는 재조합 단백질 생산
US20220267369A1 (en) * 2018-07-25 2022-08-25 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from a production protein in chromatographic processes
KR20220069043A (ko) * 2019-09-23 2022-05-26 머크 샤프 앤드 돔 코포레이션 감소된 숙주 세포 단백질 및 증가된 폴리소르베이트-80 안정성을 갖는 항-ctla4 모노클로날 항체를 포함하는 방법 및 조성물
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2261230T1 (sl) 2002-09-11 2017-08-31 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
KR101401159B1 (ko) * 2005-12-12 2014-05-29 에프. 호프만-라 로슈 아게 가변 부위에 글리코실화를 가지는 아밀로이드 베타에 대한 항체
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
WO2011073389A1 (en) 2009-12-18 2011-06-23 Novartis Ag Wash solution and method for affinity chromatography
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
JP2016519145A (ja) 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
ES2833100T3 (es) * 2013-07-01 2021-06-14 Csl Behring Ag Procedimiento
CN105473612A (zh) * 2013-08-19 2016-04-06 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
SG11201601823TA (en) * 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
CN103497248B (zh) * 2013-09-22 2016-08-10 中国抗体制药有限公司 一种从细胞培养上清中分离纯化抗体的方法
BR112018001511A2 (pt) 2015-08-21 2018-09-18 Hoffmann La Roche ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano
JP7073253B2 (ja) 2015-08-21 2022-05-23 エフ．ホフマン－ラ ロシュ アーゲー アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法

Also Published As

Publication number Publication date
CN116063375A (zh) 2023-05-05
SI3337812T1 (sl) 2021-08-31
WO2017032686A1 (en) 2017-03-02
US20180186832A1 (en) 2018-07-05
IL257146A (en) 2018-03-29
HRP20211026T1 (hr) 2021-10-01
JP2023076617A (ja) 2023-06-01
KR20180034500A (ko) 2018-04-04
JP6968055B2 (ja) 2021-11-17
CA2992420A1 (en) 2017-03-02
AU2016312909B2 (en) 2022-12-08
CN107849087A (zh) 2018-03-27
CN107849087B (zh) 2022-09-06
JP2021176900A (ja) 2021-11-11
JP2018531895A (ja) 2018-11-01
HK1251584A1 (zh) 2019-02-01
MX2018001536A (es) 2018-04-24
PL3337812T3 (pl) 2021-10-11
JP7258964B2 (ja) 2023-04-17
EP3337812B1 (en) 2021-04-28
EP3337812A1 (en) 2018-06-27
US20220169675A1 (en) 2022-06-02
AU2016312909A1 (en) 2018-02-22
ES2877532T3 (es) 2021-11-17

Similar Documents

Publication Publication Date Title
BR112018001511A2 (pt) ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
BR112017026330A2 (pt) molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12016500943A1 (en) Aplnr modulatros and uses thereof
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112018008577A2 (pt) anticorpos que neutralizam o vírus sincicial respiratório humano
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
BR112015031883A2 (pt) anti-pd-1 anticorpo e o uso dele
BR112015021979A2 (pt) Anticorpos humanos para grem1
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
WO2014159595A3 (en) Human antibodies to nav1.7
WO2015089492A3 (en) Dna antibody constructs and method of using same
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]